Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 56Carcinoma, Non-Small-Cell Lung 53Carcinoma, Renal Cell 37Lung Neoplasms 22Neoplasm Metastasis 21Carcinoma, Hepatocellular 21Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Neoplasms 17Colorectal Neoplasms 17Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 13Prostatic Neoplasms 11Hodgkin Disease 11Brain Neoplasms 10Urinary Bladder Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Skin Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Breast Neoplasms 7Sarcoma 6Carcinoma, Merkel Cell 6Carcinoma, Basal Cell 6Uveal Melanoma 5

Interventions

relatlimab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1Nivolumab 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × Nivolumab × 90 days × Clear all
NCT03607890 2026-03-16

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
38 enrolled

Turcot syndrome, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡